Profusa Stock Set to Reverse Split on Tuesday, July 7th (NASDAQ:PFSA)

Profusa, Inc. (NASDAQ:PFSA)’s stock is set to reverse split before the market opens on Tuesday, July 7th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, July 6th.

Profusa Stock Performance

PFSA stock remained flat at $0.09 during midday trading on Friday. The company had a trading volume of 6,920,470 shares, compared to its average volume of 7,929,186. Profusa has a fifty-two week low of $0.08 and a fifty-two week high of $180.00. The business has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $2.53.

Profusa (NASDAQ:PFSA) last posted its earnings results on Friday, May 15th. The company reported ($2.05) EPS for the quarter.

Analysts Set New Price Targets

PFSA has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Profusa presently has a consensus rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.